share_log

Credit Suisse Maintains Neutral on Monte Rosa Therapeutics, Lowers Price Target to $11

Benzinga ·  Mar 17, 2023 10:42

Credit Suisse analyst Richard Law maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Neutral and lowers the price target from $12 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment